Pennant Group (PNTG) has stepped up its expansion efforts, advancing a collaboration with Hartford HealthCare in Connecticut while also assuming operations of a 46 unit memory care community in Pleasant Hill, California.

These expansion moves come as the stock trades at US$31.71, with a 1-day share price return of 5.28% and a 30-day share price return down 11.67%. The 3-year total shareholder return of about 1.5x suggests earlier momentum has been much stronger than the past year.

If Pennant’s healthcare focus has your attention, it can be useful to see what else is gaining traction in the sector by scanning 38 healthcare AI stocks.

With Pennant Group investing in both home based care and senior living, and the stock up over the past year but softer in recent months, are you looking at an undervalued compounder here or is the market already pricing in future growth?

Most Popular Narrative: 16.9% Undervalued

At $31.71, the most followed narrative places Pennant Group’s fair value at about $38.17, framing the current price as meaningfully below that estimate.

The continued shift in health care delivery toward lower cost, home based settings reinforced by government and payer priorities to control costs and improve patient satisfaction directly benefits Pennant's core business lines, and as patients and families increasingly prefer home care, management expects above industry growth rates and margin expansion from operating leverage.

Want to see what sits behind that confidence in higher margins and faster growth? The narrative leans on ambitious revenue expansion, rising profitability and a richer future earnings multiple.

Result: Fair Value of $38.17 (UNDERVALUED)

However, this depends on key risks, including potential reimbursement cuts and higher labor costs. These factors could pressure margins and challenge the upbeat fair value narrative.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Earnings Multiple Sends a Caution Flag

Those optimistic fair value estimates sit awkwardly beside Pennant Group’s current P/E of 36.4x, which is higher than both the US Healthcare industry average of 23.8x and the peer average of 33.3x, as well as above a fair ratio of 27.1x. This raises the question of whether the market is already paying up for this story.

Next Steps

Mixed messages on value and risk so far? Move quickly from second hand sentiment to your own view by checking the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you may miss opportunities that fit your style far better, so put a few more options on your radar today.

• Target potential mispricings by scanning companies that currently look cheap on quality and value metrics using the 48 high quality undervalued stocks.
• Strengthen your focus on resilience by screening for businesses with robust finances through the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by spotting under-the-radar opportunities using a screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.